Change from Vitamin K Antagonist to Factor Xa inhibitor Improves Pulse Wave Velocity

Change from Vitamin K Antagonist to Factor Xa inhibitor Improves Pulse Wave Velocity - K2-SUMMIT 3

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016459

Enrollment

Registered

2015-02-10

Start date

2015-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular atrial fibrillation requiring anti-coagulation therapy

Interventions

Rivaroxaban Warfarin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non valvular atrial fibrillation treated with warfarin for more than 6 months but less than 10 years

Exclusion criteria

Exclusion criteria: 1) contraindication against warfarin and/or rivaroxaban 2) pregnant woman 3) peripheral artery disease difficult to measure pulse wave velocity 4) unstable blood pressure 5) under dual antiplatelet therapy 6) younger than 21 years old

Design outcomes

Primary

Measure	Time frame
Improvement of pulse wave velocity 3 months after drug change	—

Secondary

Measure	Time frame
uncarboxylated osteocalcin, high sensitive C-reactive protein and clinical outcomes including death, myocardial infarction, stroke and major bleeding according to ISTH definition	—

Countries

Japan

Contacts

Public ContactFumie Saito

Tokai University Cardiology

f.saito@tokai-u.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026